Streetbeat News

Products Services

LXRX

Lexicon Pharmaceuticals' new analysis of Phase 3 data shows that INPEFA benefits heart failure patients regardless of diabetes duration, with greater benefits for those with longer diabetes duration. The findings were presented at the ESC Congress 2024.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:20 pm

ESPR

Esperion has secured additional commercial and Medicare formulary coverage for its drugs NEXLETOL and NEXLIZET, now covering over 65% of Medicare insured lives and 92% of commercially insured lives. This expanded coverage follows FDA approval of expanded indications, making it easier for healthcare providers to prescribe these non-statin drugs.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:18 pm

ARMK

BBY

GM

SN

VOXX

Five consumer discretionary stocks, including VOXX International, Aramark, Sharkninja, General Motors, and Best Buy, are currently overbought according to RSI indicators. These stocks have shown significant price increases recently, but their high RSI values suggest potential short-term price corrections.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 12:17 pm

CUE

Cue Biopharma will present at The Promise of Interleukin-2 Therapy Conference in Paris, showcasing their novel therapeutic biologics, including CUE-401 and the CUE-100 series, aimed at enhancing T cell engagement for cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:17 pm

MRNA

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of Moderna's Spikevax COVID-19 vaccine, which targets the JN.1 subvariant. This approval could potentially boost Moderna's market position and sales.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:14 pm

ASO

Academy Sports + Outdoors (ASO) plans to open 9 new stores in fall 2024, expanding its presence across eight states. This is part of their strategy to open 15-17 new stores in fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:11 pm

COGT

Cogent Biosciences has completed patient enrollment for its Phase 3 PEAK trial evaluating Bezuclastinib with Sunitinib. The trial enrolled 413 patients, and an interim analysis recommended continuation. Top-line results are expected by the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:10 pm

RIGL

Rigel Pharmaceuticals has expanded its partnership with Kissei Pharmaceutical to include the development and commercialization of REZLIDHIA in Japan, Korea, and Taiwan. Rigel will receive a $10M upfront payment and could earn up to $152.5M in milestone payments.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:08 pm

RGNX

REGENXBIO reported positive data from its Phase I/II/III trial of RGX-121 for treating Mucopolysaccharidosis Type II, showing long-term systemic effects. The results were presented at the SSIEM Annual Symposium 2024.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:08 pm

ELAB

Elevai Labs' stock is rising following positive data results from its subsidiary, Elevai Skincare, on the potential of Elevai Exosomes in hair restoration.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:06 pm